The deal, signed on Sept. 9 and quietly tabled late last month, is to be ratified, behind closed doors, within just 21 sitting days and without any public hearings. Legislators on the trade committee were briefed for just one hour by government officials last week, with no independent witnesses present.
To any Taiwanese who has tracked the style of negotiations between President Ma Ying-jeou’s (馬英九) administration and China in the past four years, the situation described above will sound eerily familiar.
However, the deal in question is not the Economic Cooperation Framework Agreement (ECFA) signed in 2010 after six months of negotiations, or the investment protection agreement inked on Aug. 9. It is the Foreign Investment and Protection Agreement (FIPA) between China and Canada, which critics say requires public scrutiny and risks putting Canada at a disadvantage.
However, the Conservative government of Canadian Prime Minister Stephen Harper refuses to hold public hearings and seems intent on forging ahead with an agreement that even its supporters admit contains flaws.
Among the most alarming aspects of the deal are its 31-year lifespan, in contrast with the six months’ warning necessary for Ottawa to pull out of the North American Free Trade Agreement (NAFTA), and the failure by Canadian negotiators to ensure that investors receive “national treatment” in China, which means that, at best, Canadian investors in China can expect treatment similar to that enjoyed by domestic Chinese firms. Moreover, Canada would be barred from imposing conditions favoring Canadian workers or resources for projects within Canada and it would be forced to restrict domestic access to fossil fuels, uranium, forests, fish and all other exhaustible resources in equal measure to any restrictions placed on exports to China, as Green Party Leader Elizabeth May said in an Oct. 1 press release.
Needless to say, such clauses are cause for concern when one deals with a resource-hungry rising power like China, whose state-owned firms are in the process of acquiring a large segment of Canada’s oil companies and fields, such as the proposed US$15 billion Nexen deal.
Then there is the clause that allows Chinese state-owned enterprises to sue the Canadian government for laws, regulations and court decisions that could “interfere with or prevent present or future profits.” While NAFTA contains similar provisions, FIPA goes further, as litigation could be done in secret with special tribunals, in which only the federal government can participate, leaving local governments and firms out in the cold.
The problem with all this is that investment between Canada and China is likely to be mostly one-way, with Chinese investment vastly outgunning that from Canada. This means that the risks are mostly Canada’s.
The Taiwanese government should pay close attention to what transpires between Canada and China in the coming months and years, as Beijing’s behavior and that of Chinese companies could provide important clues as to how they might behave in Taiwan. There are many instances of overlap, in which “unjust” clauses tend to favor China, and those could gain in importance as Taipei further opens up the country to Chinese investment.
It has often been said that Taiwan’s engagement with China can serve as a model for the international community and as a means to “predict” Beijing’s behavior. It is now apparent that Taiwan is not the only country that is facing skewed agreements. It may not have Canada’s natural resources, but intellectual property rights and company secrets in key high-tech sectors are just as likely to be targeted by Chinese investors. Most assuredly, Taiwan can learn a few things from Canada’s FIPA experience with China.
Taking advantage of my Taipei Times editors’ forbearance, I thought I would go with a change of pace by offering a few observations on an interesting nature topic, the many varieties of snakes in Taiwan. I will be drawing on my experiences living in Taiwan five times, from my teenage years in Kaohsiung back in the early sixties, to my last assignment as American Institute in Taiwan Director in 2006-9. Taiwan, with its semitropical climate, is a perfect setting for serpents. Indeed, one might say serpents are an integral part of the island’s ecosystem. Taiwan is warm, humid, with lots of
China constantly seeks out ways to complain about perceived slights and provocations as pretexts for its own aggressive behavior. It is both victimization paranoia and a form of information warfare that keeps the West on the defensive. True to form, China objected even to the innocuous reference to Taiwan at April 16’s summit meeting between US President Joe Biden and Japanese Prime Minister Yoshihide Suga. Neither leader’s prepared remarks even mentioned Taiwan, out of deference to the Japanese side. Biden’s opening statement was modest: “Prime Minister Suga and I affirmed our ironclad support for US-Japanese alliance and for our shared security.
Determined to keep a permanent grip on power, Chinese President Xi Jinping (習近平) has abandoned former paramount leader Deng Xiaoping’s (鄧小平) dogma of “hiding our capacities and biding our time” along with the “peaceful development” line that prevailed under former Chinese presidents Jiang Zemin (江澤民) and Hu Jintao (胡錦濤). Instead, he is treading a “wolf warrior” path of diplomacy that resorts to coercion, debt entrapment and hostage-taking. Externally, Xi’s China has claimed that it would never seek hegemony, yet it challenges the free, rules-based international order wherever it can. While insisting that it will not export its ideology, it has
As the US’ mass COVID-19 vaccination campaign continues at a record pace, one question under debate is what the administration of US President Joe Biden should do with its extra doses — and especially where to send them. One country that should be at the top of a donation list is Taiwan, in recognition of the help that it provided to the US at the outset of the COVID-19 pandemic last year. After weeks of pressure, the Biden administration announced that it is now “looking at options to share American-made AstraZeneca vaccine doses.” By summer, it is clear that anyone in the